MedTrace Logo

Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)

NCT01928901 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2014-07-01

No results posted yet for this study

Summary

Proof of concept: Superiority of Bronchipret or Sinupret to placebo in respect to mucociliary clearance

Conditions

  • Current Smokers

Interventions

DRUG

administration of Sinupret

DRUG

administration of Bronchipret

DRUG

administration of Sinupret Placebo

DRUG

administration of Bronchipret Placebo

Sponsors & Collaborators

  • Bionorica SE

    lead INDUSTRY

Principal Investigators

  • Claus Bachert, Prof.Dr.Dr. · University Hospital, Ghent

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2013-12-31
Completion
2014-02-28

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01928901 on ClinicalTrials.gov